290 related articles for article (PubMed ID: 33293236)
1. Hyaluronic Acid in Postmenopause Vaginal Atrophy: A Systematic Review.
Dos Santos CCM; Uggioni MLR; Colonetti T; Colonetti L; Grande AJ; Da Rosa MI
J Sex Med; 2021 Jan; 18(1):156-166. PubMed ID: 33293236
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect of noninvasive radiofrequency with vaginal estrogen and vaginal moisturizer in the treatment of vulvovaginal atrophy in postmenopausal women: a randomized clinical trial.
Gueldini de Moraes AV; Costa-Paiva L; da Costa Machado H; Maciel TF; Mariano FV; Pedro AO
Menopause; 2024 Apr; 31(4):288-302. PubMed ID: 38412393
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Efficacy of Vaginal Hyaluronic Acid to Estrogen for the Treatment of Vaginal Atrophy in Postmenopausal Women: A Systematic Review.
Albalawi NS; Almohammadi MA; Albalawi AR
Cureus; 2023 Aug; 15(8):e44191. PubMed ID: 37767255
[TBL] [Abstract][Full Text] [Related]
9. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?
Stute P
Arch Gynecol Obstet; 2013 Dec; 288(6):1199-201. PubMed ID: 24178484
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid in vulvar and vaginal administration: evidence from a literature systematic review.
Buzzaccarini G; Marin L; Noventa M; Vitagliano A; Riva A; Dessole F; Capobianco G; Bordin L; Andrisani A; Ambrosini G
Climacteric; 2021 Dec; 24(6):560-571. PubMed ID: 33759670
[TBL] [Abstract][Full Text] [Related]
11. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
Archer DF
J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
[TBL] [Abstract][Full Text] [Related]
12. Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy.
Pérez-López FR; Vieira-Baptista P; Phillips N; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):740-745. PubMed ID: 34036849
[TBL] [Abstract][Full Text] [Related]
13. Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial.
Bumphenkiatikul T; Panyakhamlerd K; Chatsuwan T; Ariyasriwatana C; Suwan A; Taweepolcharoen C; Taechakraichana N
BMC Womens Health; 2020 Aug; 20(1):173. PubMed ID: 32787848
[TBL] [Abstract][Full Text] [Related]
14. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
15. Polycarbophil vaginal moisturizing gel versus hyaluronic acid gel in women affected by vaginal dryness in late menopausal transition: A prospective randomized trial.
Cagnacci A; Barattini DF; Casolati E; Pecoroni A; Mangrella M; Patrascu LC
Eur J Obstet Gynecol Reprod Biol; 2022 Mar; 270():239-245. PubMed ID: 35131532
[TBL] [Abstract][Full Text] [Related]
16. Dyspareunia Related to GSM: Association of Total Vaginal Thickness via Transabdominal Ultrasound.
Balica AC; Cooper AM; McKevitt MK; Schertz K; Wald-Spielman D; Egan S; Bachmann GA
J Sex Med; 2019 Dec; 16(12):2038-2042. PubMed ID: 31542351
[TBL] [Abstract][Full Text] [Related]
17. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis.
Simon JA; Ferenczy A; Black D; Castonguay A; Royer C; Marouf R; Beauchemin C
Menopause; 2023 Aug; 30(8):855-866. PubMed ID: 37369079
[TBL] [Abstract][Full Text] [Related]
19. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
Constantine G; Millheiser LS; Kaunitz AM; Parish SJ; Graham S; Bernick B; Mirkin S
Menopause; 2019 Nov; 26(11):1259-1264. PubMed ID: 31688572
[TBL] [Abstract][Full Text] [Related]
20. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
[No Abstract] [Full Text] [Related]
[Next] [New Search]
